Boundless Bio has announced a strategic portfolio prioritization aimed at optimizing its oncology programs, particularly focusing on the combination therapy of BBI-355 and BBI-825, alongside a new ...
Boundless Bio has finally given on its hopes on finding redemption for two solid tumor drugs that had both come up short in the clinic by packaging them up as a combination treatment. The Californian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results